#	Pagina
attuale pagina	/open-h2020/projects/194081/index.html
-1	/open-h2020/projects/222354/index.html
-2	/open-h2020/projects/224599/index.html
-3	/open-h2020/projects/195261/index.html
-4	/open-h2020/projects/210257/index.html
-5	/open-h2020/projects/193450/deliverables.html

Opendata, web and dolomites

RETHRIM SIGNED

Restoring tissue regeneration in patients with visceral Graft versus Host Disease.

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

RETHRIM project word cloud

Explore the words cloud of the RETHRIM project. It provides you a very rough idea of what is the project "RETHRIM" about.

trial expertise quality gvhd regenerative regeneration efficacy direct treatment stepping commercialization hold msc promise graft capacity injury relies clinical shown serve disorders infrastructure patients harmonized drug tissues tissue acute resistant cell cartilage mechanism central signature organ molecular stromal intend mechanisms 150 designation randomized body first beginning versus therapy disease placebo date thereby positive published rethrim combined potency variety steroid stem undergoing academic prediction collect once outcome mesenchymal therapeutic additional form host anti life latter analysed orphan endogenous cells functional extensively therapies ethical data repair stone visceral bone markers conduct health recruited hampering safety progenitor inflammatory indirect suffering

Project "RETHRIM" data sheet

The following table provides information about the project.

Coordinator	ACADEMISCH ZIEKENHUIS LEIDEN Organization address address: ALBINUSDREEF 2 city: LEIDEN postcode: 2333 ZA website: www.lumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.rethrim.eu
Total cost	5˙857˙587 €
EC max contribution	5˙857˙587 € (100%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-PHC-2014-single-stage
Funding Scheme	RIA
Starting year	2015
Duration (year-month-day)	from 2015-01-01 to 2021-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ACADEMISCH ZIEKENHUIS LEIDEN ACADEMISCH ZIEKENHUIS LEIDEN Organization address address: ALBINUSDREEF 2 city: LEIDEN postcode: 2333 ZA website: www.lumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	coordinator	2˙334˙931.00
2	UNIVERSITAET LEIPZIG UNIVERSITAET LEIPZIG Organization address address: RITTERSTRASSE 26 city: LEIPZIG postcode: 4109 website: www.uni-Ieipzig.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (LEIPZIG)	participant	660˙043.00
3	IMMUNOTOOLS GMBH IMMUNOTOOLS GMBH Organization address address: Altenoyther Str. 10 city: Friesoythe postcode: 26169 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (Friesoythe)	participant	534˙025.00
4	FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON FUNDACION INSTITUTO DE ESTUDIOS DE CIENCIAS DE LA SALUD DE CASTILLA Y LEON Organization address address: PARQUE SANTA CLARA city: SORIA postcode: 42002 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (SORIA)	participant	399˙787.00
5	GenomeScan B.V. GenomeScan B.V. Organization address address: Plesmanlaan 1d city: Leiden postcode: 2333 BZ website: www.genomescan.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (Leiden)	participant	370˙000.00
6	KATHOLIEKE UNIVERSITEIT LEUVEN KATHOLIEKE UNIVERSITEIT LEUVEN Organization address address: OUDE MARKT 13 city: LEUVEN postcode: 3000 website: www.kuleuven.be contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (LEUVEN)	participant	354˙850.00
7	LUNDS UNIVERSITET LUNDS UNIVERSITET Organization address address: Paradisgatan 5c city: LUND postcode: 22100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (LUND)	participant	333˙200.00
8	OSPEDALE PEDIATRICO BAMBINO GESU OSPEDALE PEDIATRICO BAMBINO GESU Organization address address: PIAZZA SANT ONOFRIO 4 city: ROMA postcode: 165 website: www.ospedalebambinogesu.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	participant	331˙537.00
9	ERASMUS UNIVERSITEIT ROTTERDAM ERASMUS UNIVERSITEIT ROTTERDAM Organization address address: BURGEMEESTER OUDLAAN 50 city: ROTTERDAM postcode: 3062 PA website: www.eur.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (ROTTERDAM)	participant	309˙300.00
10	KAROLINSKA INSTITUTET KAROLINSKA INSTITUTET Organization address address: Nobels Vag 5 city: STOCKHOLM postcode: 17177 website: www.ki.se contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	SE (STOCKHOLM)	participant	229˙912.00
11	GENOMIC INVESTMENTS BV GENOMIC INVESTMENTS BV Organization address address: PLESMANLAAN 1D city: LEIDEN postcode: 2333 BZ website: www.servicexs.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (LEIDEN)	participant	0.00
12	STICHTING HEMATO-ONCOLOGIE VOOR VOLWASSENEN NEDERLAND (HOVON) STICHTING HEMATO-ONCOLOGIE VOOR VOLWASSENEN NEDERLAND (HOVON) Organization address address: De Boelelaan 1117 city: Amsterdam postcode: 1081 HV website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (Amsterdam)	participant	0.00

Map

Project objective

Stem cell regenerative therapies hold great promise for patients suffering from a variety of disorders that are associated with tissue or organ injury. Regeneration relies on tissue or organ-specific stem and progenitor cells, but can also aim at promoting the endogenous repair capacity of the body.

Mesenchymal stromal cells (MSC) are undergoing clinical testing in a variety of clinical conditions aiming at repair through direct or indirect mechanisms. Their ability to form bone or cartilage is used to directly repair these tissues. In other conditions their regenerative effects are based on endogenous repair through their anti-inflammatory properties. The latter mechanism is important in the treatment of acute Graft-versus-Host Disease (GvHD). We have been involved in the clinical development from the beginning and we have shown the therapeutic potential. However, no results of controlled randomized phase 3 studies have been published to date, thereby hampering safety and efficacy assessment.

Within our consortium we have developed an academic infrastructure for the harmonized production of MSC. In the RETHRIM proposal this will be combined with our clinical expertise to conduct the first Europe-wide placebo controlled randomized phase III trial using MSC regenerative therapy for the treatment of steroid-resistant visceral GvHD. Central to the RETHRIM project is the clinical trial for which 150 patients will be recruited. All MSC products will be extensively analysed using molecular and functional markers, in order to develop a potency signature for the product and for the prediction of response. We also intend to collect data from additional quality of life, health technology assessment and ethical studies. We will apply for an Orphan Drug Designation in Europe and this may serve as a stepping-stone for the further commercialization of the MSC product, once a positive outcome has been obtained.

Deliverables

List of deliverables.
Website	Websites, patent fillings, videos etc.	2020-02-12 08:28:27

Take a look to the deliverables list in detail: detailed list of RETHRIM deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	Frederick W. Thielen, Hedwig M. Blommestein, Liesbeth E.M. Oosten, Friso G. Calkoen, Arjan C. Lankester, Jaap J. Zwaginga, Katarina Le Blanc, Alba Redondo, Fermin SÃ¡nchez-Guijo, Mattia Algeri, Franco Locatelli, Wim E. Fibbe, Carin A. Uyl-de Groot Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model published pages: 676-683, ISSN: 0902-4441, DOI: 10.1111/ejh.13158	European Journal of Haematology 101/5	2020-02-12
2016	Koen Schepers, Willem E. Fibbe Unraveling mechanisms of mesenchymal stromal cell-mediated immunomodulation through patient monitoring and product characterization published pages: 15-23, ISSN: 0077-8923, DOI: 10.1111/nyas.12984	Annals of the New York Academy of Sciences 1370/1	2020-02-12

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RETHRIM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RETHRIM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination